In California, Codexis, Inc. and Nestlé Health Science announced a strategic collaboration encompassing multiple projects accessing Codexis’ CodeEvolver protein engineering platform. The collaboration includes an option for the global development of Codexis’ novel, orally delivered, enzyme for the management of phenylketonuria, an orphan metabolic disorder.
Greg Behar, CEO of Nestlé Health Science, stated, “Enzymes are key to healthy functioning. When enzymes are not present or not working properly there can be an impairment of a wide range of processes critical for human health. The partnership with Codexis strengthens our footprint in the enzyme field, a fast developing part of the nutritional therapy innovation frontier that is changing the way we manage our health.”
Nestlé Health Science has secured strategic access to CodeEvolver for the discovery of biotherapeutics for other metabolic disorders, and for the development of novel enzyme products for Nestlé Health Science’s Medical Nutrition and Consumer Care business areas.